Gamida Cell looks to get $22M+ on its public offering launch; Esperion signs co-promotion pact with Currax
The cell therapy biotech Gamida Cell went forward with its public offering on the back of FDA approval for Omisirge (omidubicel-onlv), its allogeneic cord …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
